Frontiers in Cardiovascular Medicine · 2022 · 15 citations · 21 references
MedicineCardiologySurgeryCardiothoracic SurgeryInterventional CardiologyVascular SurgeryAortic StenosisCardiac Valve SurgeryTranscatheter Valve TherapyTricuspid Valve DiseaseValvular Heart DiseaseBicuspid Aortic Valve StenosisIn-hospital MortalityPrimary Outcome AnalysisTranscatheter Tricuspid Valve InterventionTricuspid StenosisValves
Objectives Patients with bicuspid aortic valve (BAV) stenosis were excluded from the pivotal trials of transcatheter aortic valve implantation (TAVI). We compared the in-hospital and long-term outcomes between patients undergoing TAVI for bicuspid and tricuspid aortic valve (TAV) stenosis. Methods We performed a retrospective registry-based analysis on patients who underwent TAVI for BAV and TAV at five different centers between January 2009 and August 2017. The primary outcome was long-term all-cause mortality. Secondary outcomes were in-hospital mortality, procedural complications, and valve performance. Results Of 1,451 consecutive patients who underwent TAVI, two propensity-matched cohorts consisting of 130 patients with BAV and 390 patients with TAV were analyzed. All-cause mortality was comparable in both groups up to 10 years following TAVI ( HR 1.09, 95% CI : 0.77–1.51). Device success and in-hospital mortality were comparable between the groups (96 vs. 95%, p = 0.554 and 2.3 vs. 2.1%, p = 0.863, respectively). Incidence of procedural complications was similar in both groups, with a trend toward a higher rate of stroke in patients with BAV (5 vs. 2%, p = 0.078). Incidence of moderate or severe paravalvular leak (PVL) at discharge was comparable in both groups (2 vs. 2%, p = 0.846). Among patients with BAV, all-cause mortality was similar in self-expanding and balloon-expandable prostheses ( HR 1.02, 95% CI : 0.52–1.99) and lower in new-generation devices compared to old-generation valves ( HR 0.27, 95% CI 0.12–0.62). Conclusion Patients who had undergone TAVI for BAV had comparable mortality to patients with TAV up to 10 years after the procedure. The device success, in-hospital mortality, procedural complications, and PVL rate were comparable between the groups. The high rate of neurological complications (5%) in patients with BAV warrants further investigation.
21
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Helmut Baumgartner, Volkmar Falk, Jeroen J. Bax et al. · European Heart Journal · 2017 · 6.3K citations · Full text
Medicine, Cardiology, Surgery +14
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis
David Adams, Jeffrey J. Popma, Michael J. Reardon et al. · New England Journal of Medicine · 2014 · 2.9K citations · Full text
Medicine, Cardiology, Surgery +13
Incidence of Aortic Complications in Patients With Bicuspid Aortic Valves
Héctor I. Michelena, Amber Khanna, Douglas W. Mahoney et al. · JAMA · 2011 · 822 citations
Medicine, Cardiology, Surgery +17
Aortic Dilatation in Patients with Bicuspid Aortic Valve
Subodh Verma, Samuel C. Siu · New England Journal of Medicine · 2014 · 495 citations
Medicine, Cardiology, Surgery +12